Top

Gepubliceerd in:

05-09-2017 | Commentary

Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al

Auteurs: Karin Ribi, Alan Coates, Lynette Blacher, Meredith M. Regan, Richard D. Gelber, Jürg Bernhard

Gepubliceerd in: Quality of Life Research | Uitgave 1/2018

Excerpt

In 2016, a publication on health-related quality of life (HRQoL) assessment in patients with breast cancer reported on a systematic and standardized comparison of available instruments using the evaluation measures of patient-reported-outcomes (EMPRO) tool [1]. In this review, eight HRQoL measures were compared including 32 studies reporting on psychometric properties or the validation process. One of the instruments included in this review is the International Breast Cancer Study Group (IBCSG) quality of life (QoL) Core Form [2]. Although we are pleased that the IBCSG QoL Core Form could be recommended for assessing health-related quality of life in breast cancer [1], the description of specific characteristics of the IBCSG form and the rating of this instrument based on EMPRO [3] requires clarification and further discussion of the development research overlooked during the rating. Although Maratia et al. [1] conducted a predefined systematic search and selection of papers, they used only a summary paper that was published in 1997 to describe the IBCSG approach [2]. More detailed psychometric data for the IBCSG QoL Core Form have been published in many other studies as described in the following paragraphs. …

vorige artikel Combat exposure, emotional and physical role limitations, and substance use among male United States Army Reserve and National Guard soldiers

volgende artikel The relationship of five boarding school experiences and physical health status among Northern Plains Tribes

Maratia, S., Cedillo, S., & Rejas, J. (2016). Assessing health-related quality of life in patients with breast cancer: A systematic and standardized comparison of available instruments using the EMPRO tool. Quality of Life Research, 25(10), 2467–2480. doi:10.1007/s11136-016-1284-8.CrossRefPubMed

Bernhard, J., Hürny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1997). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Annals of Oncology, 8(9), 825–835.CrossRefPubMed

Valderas, J. M., Ferrer, M., Mendivil, J., Garin, O., Rajmil, L., Herdman, M., et al. (2008). Development of EMPRO: A tool for the standardized assessment of patient-reported outcome measures. Value Health, 11(4), 700–708. doi:10.1111/j.1524-4733.2007.00309.x.CrossRefPubMed

Bernhard, J., Peterson, H. F., Coates, A. S., Gusset, H., Isley, M., Hinkle, R., et al. (1998). Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: Practical issues and factors associated with missing data. Statistics in Medicine, 17(5–7), 587–601.CrossRefPubMed

Butow, P., Coates, A., Dunn, S., Bernhard, J., & Hurny, C. (1991). On the receiving end. IV: Validation of quality of life indicators. Annals of Oncology, 2(8), 597–603.CrossRefPubMed

Bernhard, J., Sullivan, M., Hurny, C., Coates, A. S., & Rudenstam, C. M. (2001). Clinical relevance of single item quality of life indicators in cancer clinical trials. British Journal of Cancer, 84(9), 1156–1165.CrossRefPubMedPubMedCentral

Hurny, C., Bernhard, J., Coates, A., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1996). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Medical Care, 34(3), 234–248.CrossRefPubMed

Hurny, C., Bernhard, J., Bacchi, M., van Wegberg, B., Tomamichel, M., Spek, U., et al. (1993). The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Supportive Care in Cancer, 1(4), 200–208.CrossRefPubMed

Hürny, C., van Wegberg, B., Bacchi, M., Bernhard, J., Thürlimann, B., Ral, O., et al. (1998). Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for cancer clinical trials. British Journal of Cancer, 77, 985–991.CrossRefPubMed

10.

Michels, F. A. S., Latorre, R. D. O., & Maciel, M. S. (2010). Validation, reliability, and comprehension of the IBCSG quality of life questionnaire specifi to Breast Cancer. Applied Cancer Research, 30(4), 348–352.

11.

Hurny, C., Bernhard, J., Gelber, R. D., Coates, A., Castiglione, M., Isley, M., et al. (1992). Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. The International Breast Cancer Study Group. European Journal of Cancer, 28(1), 118–124.CrossRefPubMed

12.

Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health, 8(2), 94–104. doi:10.1111/j.1524-4733.2005.04054.x.CrossRefPubMed

13.

Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., et al. (1983). On the receiving end–patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology, 19(2), 203–208.CrossRefPubMed

14.

Coates, A., Glasziou, P., & McNeil, D. (1990). On the receiving end–III. Measurement of quality of life during cancer chemotherapy. Annals of Oncology, 1(3), 213–217.CrossRefPubMed

15.

International Breast Cancer Study G, Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., et al. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. Journal of Clinical Oncology, 24(3), 337–344. doi:10.1200/JCO.2005.01.5784.CrossRef

16.

Hurny, C., Bernhard, J., Coates, A. S., Castiglione-Gertsch, M., Peterson, H. F., Gelber, R. D., et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet, 347(9011), 1279–1284.

17.

Bernhard, J., Zahrieh, D., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., et al. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British Journal of Cancer, 98(1), 25–33. doi:10.1038/sj.bjc.6604092.CrossRefPubMed

18.

Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R. D., Forbes, J. F., et al. (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology, 25(3), 263–270.CrossRefPubMed

19.

Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., et al. (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncology, 16(7), 848–858. doi:10.1016/S1470-2045(15)00049-2.CrossRefPubMed

20.

Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Bellet, M., et al. (2016). Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen-alone in premenopausal women with early breast cancer: patient-reported outcome in the SOFT trial. Journal of Clinical Oncology, 34(14), 1601–1610.CrossRefPubMedPubMedCentral

21.

Bernhard, J., Castiglione-Gertsch, M., Schmitz, S. F., Thurlimann, B., Cavalli, F., Morant, R., et al. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment. Swiss group for clinical cancer research (SAKK). European Journal of Cancer, 35(6), 913–920.CrossRefPubMed

22.

Bernhard, J., Thurlimann, B., Schmitz, S. F., Castiglione-Gertsch, M., Cavalli, F., Morant, R., et al. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? Journal of Clinical Oncology, 17(6), 1672–1679.CrossRefPubMed

23.

Lee, C. K., Stockler, M. R., Coates, A. S., Gebski, V., Lord, S. J., & Simes, R. J. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341–1347.CrossRefPubMedPubMedCentral

24.

Coates, A., Gebski, V., Signorini, D., Murray, P., McNeil, D., Byrne, M., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10(12), 1833–1838.CrossRefPubMed

25.

Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., et al. (2000). Quality-of-life scores predict outcome in metastatic but not early breast cancer. Journal of Clinical Oncology, 18(22), 3768–3774.CrossRefPubMed

Titel: Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al
Auteurs: Karin Ribi
Alan Coates
Lynette Blacher
Meredith M. Regan
Richard D. Gelber
Jürg Bernhard
Publicatiedatum: 05-09-2017
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 1/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-017-1695-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Excerpt

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2018

Combat exposure, emotional and physical role limitations, and substance use among male United States Army Reserve and National Guard soldiers

Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease

Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder

Development and psychometric evaluation of the PROMIS Pediatric Life Satisfaction item banks, child-report, and parent-proxy editions

The relationship of five boarding school experiences and physical health status among Northern Plains Tribes

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma